For combination product development teams, determining which performance standards apply to an autoinjector or prefilled pen — and at which level of the device hierarchy — is a recurring regulatory challenge. ISO 11040 defines finished prefilled-syringe test methods such as leakage beyond the plunger and flange break resistance, while ISO 11608 governs needle-based injection systems; understanding how FDA recognizes and applies each series is essential for designing a compliant verification and validation program.
This analysis examines which parts of ISO 11040 and ISO 11608 FDA has formally recognized, how agency guidance distinguishes testing obligations for the syringe constituent part from those for the finished delivery device, and what FDA expects when an autoinjector or prefilled pen incorporates a prefilled syringe as a component.
Want Rhizome's help on your own question? Try it for free.
Does FDA require ISO 11040 prefilled-syringe performance testing on an autoinjector or pen?
Short answer
No. FDA does not require you to run the prefilled-syringe (PFS) performance tests defined in ISO 11040 (for example, leakage past the plunger or barrel/flange break resistance) on the finished autoinjector or prefilled pen as a fixed, standard-driven checklist. Those tests belong to the ISO 11040 series, which characterizes the prefilled syringe and its components as a primary container closure, not the assembled delivery device 414. The finished injector is instead addressed by the ISO 11608 needle-based injection system (NIS) series, which FDA recognizes, and by FDA's own risk-based design-control framework, now expressed through "essential drug delivery outputs" 414860.
That said, the underlying attributes those ISO 11040 tests measure (syringe break resistance, container closure integrity, functionality across shelf life) still have to be established and controlled, and several of them frequently must be re-verified at the assembled-device level because the injector mechanism changes the forces the syringe experiences 5556. The distinction is about where and why the testing is done, not whether the attribute matters.
What ISO 11040 actually covers
ISO 11040 is a component and container standard, structured by piece part. The parts most relevant to injectable biologics are Part 4 (glass barrels and sterilized subassembled syringes ready for filling) and Part 5 (plunger stoppers for injectables); each specifies materials, dimensions, quality, performance requirements, and test methods for that component, and each explicitly notes that items needed to complete the syringe, such as the plunger stopper and plunger rod, are outside the scope of Part 4 1411.
The part that actually contains finished-syringe functional and integrity test methods is ISO 11040-8, "Requirements and test methods for finished prefilled syringes." Its scope is aseptically filled or terminally sterilized finished prefilled syringes for parenteral injection, "with focus on quality, functional performance and safety requirements, as well as relevant test methods" 46. This is the home of the PFS-level tests a reviewer typically has in mind (leakage, break resistance, and related functionality).
Two points matter for FDA strategy:
- FDA recognizes ISO 11040-4 (recognition numbers 6-511 for the 2024 edition and 6-464 for the 2015 edition + Amendment 1) and ISO 11040-5 (recognition number 6-278), tied to primary-container regulations such as 21 CFR 880.5570 and 880.5860 123.
- ISO 11040-8, the finished-PFS test-method part, does not appear as an FDA-recognized consensus standard in the recognized-standards database 123. So even at the container level, ISO 11040-8 is a reference method rather than a recognized standard you can simply declare conformity to. FDA supplements the recognized Part 4 with its own draft guidance (below) 63.
The finished injector is governed by ISO 11608, not ISO 11040
The autoinjector or pen, as an assembled product, falls under the ISO 11608 needle-based injection system series, which FDA recognizes across the family: ISO 11608-1 (systems, recognition 6-478), 11608-2 (double-ended pen needles, 6-476), 11608-3 (containers and integrated fluid paths, 6-477), 11608-4 (systems containing electronics, 6-475), 11608-5 (automated functions, 6-479), 11608-6 (on-body delivery systems, 6-480), and 11608-7 (accessibility, 6-382) 47484950515253.
ISO 11608-1 draws the boundary between the two series explicitly. It applies where the NIS incorporates a prefilled syringe, but "stand-alone prefilled syringes defined by ISO 11040-8 are not covered by this document." It goes further: functions and characteristics of the prefilled syringe such as dose accuracy remain subject to ISO 11040-8, "and not this document, unless the addition impacts the delivery function (e.g. a mechanism that intends to restrict or stop the plunger movement, which would limit the dose delivered). In that case, the system is completely covered by this document and applicable requirements of the ISO 11608 series" 41.
ISO 11608-3 covers containers and integrated fluid paths used with an NIS and "is also applicable to prefilled syringes (see ISO 11040-8) when used with a NIS" 35. In other words, the standards ecosystem intentionally hands PFS-intrinsic performance to ISO 11040 while pulling the container into ISO 11608 to the extent the device interacts with it. That interaction is exactly where finished-device testing of syringe attributes comes back into play.
FDA's actual expectation: design controls and essential drug delivery outputs
FDA does not frame its combination-product expectations as "run ISO 11040 test list X on the assembled device." It applies design controls (21 CFR 820.30 concepts) and, in its June 28, 2024 draft guidance "Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products," a framework of essential drug delivery outputs (EDDOs), which FDA describes as the design outputs "necessary to ensure delivery of the intended drug dose to the intended delivery site," covering product preparation and the initiation, progression, and completion of dose delivery 608591. FDA notes EDDO replaces the earlier term "essential performance requirements" 88.
For a typical injector, the EDDOs FDA lists as examples are functional delivery outputs, not container-integrity attributes:
- Dose accuracy and deliverable volume 5784
- Breakloose (activation) force and glide force 8284
- Cap, needle-shield, or needle-safety removal/activation force 818284
- Injection depth or extended needle length, where the device controls it independent of user technique 8284
- Withdrawal force where the same syringe is used to withdraw and deliver 82
- For emergency-use injectors, activation force, needle insertion force, injection depth, and dose accuracy feed the reliability analysis 81
Critically for this question, FDA's own EDDO example marks container closure integrity as "No" for EDDO status, because "it is not an output intended for drug delivery" 57. That does not mean CCI is unregulated; it means CCI is handled as a container closure / CMC design requirement rather than as a device drug-delivery output. The same logic applies to leakage past the plunger, which is fundamentally a container/functionality-and-integrity attribute, and to barrel/flange break resistance, which is a mechanical property of the syringe.
On acceptance criteria, FDA is deliberately non-prescriptive: design verification must confirm the design output meets the design input requirements, the criteria derive from the intended use and the product-specific EDDO specification rather than a single universal numeric threshold, and the applicant should justify why the chosen tests, conditions, and methods are adequate 9091. Where an alternative approach is used, provide the rationale and seek FDA feedback 90.
Where the ISO 11040 attributes come back at the device level
Although FDA does not mandate the ISO 11040 test suite on the finished injector, three of the attributes those tests measure routinely have to be demonstrated on, or bridged to, the assembled product.
Break resistance. FDA's draft "Bridging for Drug-Device and Biologic-Device Combination Products" guidance states that assembling a prefilled syringe into an autoinjector "could change quality considerations for the drug constituent part," and that CMC considerations "include impacts on syringe resistance to breakage, functionality throughout shelf life, and expiration dating" 55. This is the practical embodiment of the ISO 11608-1 carve-out: the autoinjector spring imposes axial and radial loads the standalone syringe never sees, so break resistance is re-evaluated in the assembled configuration 4155.
Functionality and leakage over shelf life. The same bridging logic ties "functionality throughout shelf life" to the assembled product, and FDA's ISO 11040-4 supplement guidance recommends functional attributes including injection force to depress the plunger and eject contents, tip cap removal force, and "piston seal blow back" (the ability of the syringe with tip cap to hold pressure on the piston), which is directly related to plunger leakage behavior 55101.
Additional attributes beyond ISO 11040-4. FDA's 2013 draft "Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement ISO Standard 11040-4" adds recommendations on top of the recognized Part 4, including unscrewing torque, ease of assembly, resistance to overriding, stress cracking, validation of graduation markings, dead space, coring needle testing, connectivity to needles/adapters/transfer systems, injection force, tip cap removal force, piston seal blow back, biocompatibility, and sterilization, plus performance testing of any anti-needle-stick mechanism with the glass syringe 63101. This confirms FDA treats ISO 11040-4 as a floor to be supplemented, not a complete test plan.
What can be leveraged versus regenerated. FDA's guidance recognizes that some device-level verification (for example extended needle length, activation force, cap removal force) can be leveraged independent of the drug, while drug-affected outputs (dose accuracy, injection time) are generated anew for the specific presentation 56. Leachables/extractables data developed for a PFS presentation can carry to an autoinjector presentation when the primary container closure is unchanged and the secondary autoinjector materials do not contact the drug 56.
Practical summary
| Attribute (ISO 11040 concept) | Primary "home" standard | Tested at container level? | Re-verified on finished injector? | FDA basis |
|---|---|---|---|---|
| Leakage past the plunger / plunger functionality | ISO 11040-8 (finished PFS); related to CCI | Yes, PFS constituent part | Often, as functionality-through-shelf-life in the assembled product | 455101 |
| Barrel / flange break resistance | ISO 11040-4 (barrel) and ISO 11040-8 | Yes | Frequently, because the injector mechanism changes applied loads | 144155 |
| Container closure integrity | ISO 11040-8 / CCI methods | Yes (CMC) | Assessed as CMC design requirement, not an EDDO | 457 |
| Dose accuracy / delivered volume | ISO 11040-8 for the PFS; ISO 11608 if the device affects delivery | Yes for PFS | Yes at device level when the injector affects delivery | 415784 |
| Breakloose / glide / activation / cap-removal forces | ISO 11608 series | n/a | Yes, as essential drug delivery outputs | 828460 |
Net position for a reviewer: treat ISO 11040 (especially Part 4, which FDA recognizes, and Part 8, which it does not) as the container-closure characterization for the prefilled syringe constituent part, and treat ISO 11608 plus FDA's essential-drug-delivery-output design-verification framework as the governing basis for the finished autoinjector or pen 14414860. FDA will expect you to show, through design controls, that syringe break resistance, container closure integrity, and delivery functionality are maintained in the assembled, aged product, but it will not simply require the ISO 11040 test list to be executed on the finished device 559091.
Good follow-ups to ask Rhizome
- The full list of design-verification tests and reliability targets FDA recommends in the 2013 Pen/Jet injector guidance and the 2020 emergency-use injector reliability draft (for example the 99.999% reliability at 95% confidence expectation) 596196.
- How FDA's bridging guidance sequences PFS-to-autoinjector data leverage versus regeneration for a specific change (needle, spring, or fill) 5556.
- A side-by-side of ISO 11040-4 (recognized) versus the FDA supplement's additional recommended tests 63101.
- Which recognized ISO 11608 parts to declare conformity to for a given injector architecture (standard NIS, electronics, automated functions, or on-body) 474849505153.